Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$8.27 - $18.43 $131,493 - $293,037
-15,900 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$45.28 - $74.5 $108,672 - $178,800
2,400 Added 17.78%
15,900 $754,000
Q2 2021

Aug 09, 2021

BUY
$47.86 - $83.95 $646,110 - $1.13 Million
13,500 New
13,500 $1.13 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $130M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track British Columbia Investment Management Corp Portfolio

Follow British Columbia Investment Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.